Chemotherapy probably leads to lower time to progression compared with best supportive care (moderate certainty).
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
Post‐surgical chemotherapy leads to lower disease Free Survival compared with surgery alone (high certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).